Aspen Neuroscience and Bambusa launched on Nasdaq this week, extending an IPO streak for biotech and signaling investor appetite for late-stage platforms in neurodegeneration and immunology. Aspen Neuroscience debuted as it prepares for a pivotal test of its Parkinson’s cell therapy, while Bambusa is positioning its bispecific antibodies to break through what it calls a therapeutic ceiling. Reports say both companies opened below their IPO prices amid broader market turbulence tied to NASDAQ moves and valuation concerns for AI-linked stocks. Still, the listings are expected to provide near-term cash runway and market visibility. Bambusa’s IPO raised $169 million, supporting its pipeline expansion in bispecific antibodies. Aspen’s offering brought $141 million, aimed at advancing its Parkinson’s program. Together, the debuts underline how public-market access remains available for platform-driven biotech stories—particularly those framed around clear clinical inflection points.